Rex Health Ventures

Rex Health Ventures (RHV) is a North Carolina-based private equity firm established in 2012, serving as the corporate venture capital arm of UNC REX Healthcare. The firm focuses on investing in early-stage companies within the healthcare, software as a service, life sciences, and health technology sectors. By partnering with entrepreneurs and innovative companies, RHV aims to support the development and commercialization of new treatments, tools, products, and services that enhance healthcare delivery. The firm leverages its resources and network to assist startups in overcoming challenges during their growth stages, thereby fostering innovation and improving patient care within the healthcare landscape.

Evan Bernath

Investment Associate

Steve Burriss

President and COO

Ray Jang

Senior Associate

Anita Watkins

Managing Director

Past deals in North Carolina

Pryon

Funding Round in 2021
Pryon Inc. is an artificial intelligence company headquartered in Raleigh, North Carolina, that specializes in augmented intelligence solutions for enterprises. Founded in 2017, Pryon has developed a platform that enhances the capabilities of employees by facilitating access to knowledge and streamlining workflows. The platform intelligently orchestrates information across various channels and sources, utilizing advanced AI techniques such as natural language processing and context awareness. This enables organizations to navigate unstructured data more effectively, improve decision-making, and reduce operational complexities and costs. Through its innovative approach, Pryon aims to support businesses in their digital transformation efforts by making knowledge more accessible and actionable.

Pryon

Venture Round in 2021
Pryon Inc. is an artificial intelligence company headquartered in Raleigh, North Carolina, that specializes in augmented intelligence solutions for enterprises. Founded in 2017, Pryon has developed a platform that enhances the capabilities of employees by facilitating access to knowledge and streamlining workflows. The platform intelligently orchestrates information across various channels and sources, utilizing advanced AI techniques such as natural language processing and context awareness. This enables organizations to navigate unstructured data more effectively, improve decision-making, and reduce operational complexities and costs. Through its innovative approach, Pryon aims to support businesses in their digital transformation efforts by making knowledge more accessible and actionable.

Emergo Therapeutics

Series A in 2018
Emergo Therapeutics, Inc. is a pharmaceutical company based in Durham, North Carolina, founded in 2016. The company focuses on developing therapeutic drugs aimed at modulating inflammatory cytokines and enhancing immune system function. Its primary product in development is norketotifen, which is intended for the treatment of uncomplicated influenza and flu-like illnesses. Emergo Therapeutics seeks to reduce the production of inflammatory cytokines from mast cells, with a broader goal of addressing various infectious diseases and improving health outcomes related to inflammation.

Target PharmaSolutions

Series A in 2016
TARGET PharmaSolutions, Inc. specializes in providing real-world data (RWD) solutions that facilitate drug development and commercialization. Established in 2015 and headquartered in Durham, North Carolina, the company creates customized datasets and analyses to address healthcare evidence questions. It offers a comprehensive health evidence solution that aggregates RWD from a network of clinical sites, alongside bio specimen samples and consulting services. The foundation of TARGET PharmaSolutions was influenced by the HCV-TARGET project, which began in 2011 and demonstrated the effectiveness of their model in Hepatitis C research. The initiative has garnered significant support, influencing labels for sponsors and helping to avoid costly Phase IV commitments. The FDA has actively engaged with the HCV-TARGET project, reflecting its relevance in clinical analysis and healthcare outcomes.

Phononic

Series E in 2016
Phononic, Inc. specializes in the design, prototyping, and manufacturing of innovative cooling and heating solutions, focusing on solid-state technology. Founded in 2008 and based in Durham, North Carolina, the company develops thermoelectric devices and heat pumps that replace traditional compressor technology in various applications. Its products are utilized for electronics cooling in sectors such as optoelectronics and high-performance computing, as well as in healthcare, residential, and commercial refrigeration. Phononic's thermoelectric chips, made from bismuth telluride, offer sustainable and efficient temperature control without the use of toxic refrigerants, making them suitable for industries that require precise temperature management while reducing energy consumption. The company's approach aims to deliver smart and sustainable solutions for diverse climate control needs.

Phononic

Series E in 2016
Phononic, Inc. specializes in the design, prototyping, and manufacturing of innovative cooling and heating solutions, focusing on solid-state technology. Founded in 2008 and based in Durham, North Carolina, the company develops thermoelectric devices and heat pumps that replace traditional compressor technology in various applications. Its products are utilized for electronics cooling in sectors such as optoelectronics and high-performance computing, as well as in healthcare, residential, and commercial refrigeration. Phononic's thermoelectric chips, made from bismuth telluride, offer sustainable and efficient temperature control without the use of toxic refrigerants, making them suitable for industries that require precise temperature management while reducing energy consumption. The company's approach aims to deliver smart and sustainable solutions for diverse climate control needs.

Arrivo BioVentures

Series A in 2016
Arrivo BioVentures LLC is a biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development of biologics and small molecules aimed at enhancing patient outcomes. Founded in 2015, the company focuses on drug development, leveraging its expertise to create reformulated products, new chemical entities, and biologics. Arrivo BioVentures emphasizes the importance of collaboration with regulatory bodies, such as the FDA, to streamline the approval process and efficiently execute clinical programs. By proactively engaging with regulators, the company seeks to minimize unexpected challenges and accelerate the implementation of its development programs.

Baebies

Venture Round in 2015
Baebies, Inc. is a company that focuses on manufacturing screening and pediatric testing equipment for newborns. Established in 2014 and based in Durham, North Carolina, Baebies produces SEEKER, a laboratory solution for newborn screening that conducts multiple assays simultaneously by measuring lysosomal enzyme activity from a single dried blood spot. Additionally, the company offers FINDER, a near-patient testing device designed for pediatric applications. Baebies aims to enhance early disease detection and improve diagnostic capabilities through its innovative digital microfluidics technology, which optimizes the diagnostic yield from minimal blood samples. The company serves hospitals and public health laboratories, with a mission dedicated to saving lives and improving health outcomes for children by providing advanced testing solutions.

Baebies

Series A in 2015
Baebies, Inc. is a company that focuses on manufacturing screening and pediatric testing equipment for newborns. Established in 2014 and based in Durham, North Carolina, Baebies produces SEEKER, a laboratory solution for newborn screening that conducts multiple assays simultaneously by measuring lysosomal enzyme activity from a single dried blood spot. Additionally, the company offers FINDER, a near-patient testing device designed for pediatric applications. Baebies aims to enhance early disease detection and improve diagnostic capabilities through its innovative digital microfluidics technology, which optimizes the diagnostic yield from minimal blood samples. The company serves hospitals and public health laboratories, with a mission dedicated to saving lives and improving health outcomes for children by providing advanced testing solutions.

Aerial BioPharma

Venture Round in 2012
Aerial BioPharma LLC is a biopharmaceutical company based in Morrisville, North Carolina, founded in 2011. The company specializes in drug development targeting conditions influenced by processes in the central nervous system. Aerial BioPharma is dedicated to creating both biologics and small molecules aimed at addressing various central nervous system disorders. Situated on the edge of Research Triangle Park, the company leverages its location to advance its research and development initiatives in this specialized field.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.